1Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med ,2001,345: 1368-1377.
2Marx G, Cobas Meyer M, Schuerholz T, et al. Hydroxyethyl starch and modified fluid gelatin maintain plasma volume in a porcine model of septic shock with capillary leakage. Intensive Care Medicine, 2002,28: 629-635.
3Choi PT, Yip G, Quinonez LG, et al. Crystalloids vs colloids in fluid resuscitation: a systematic review. Crit Care Med,1999,27: 200-210.
4Bellomo R, Chapman M, Finfer S, et al. Low-does dopamine in patients with early renal dysfunction: a placebo-controlled randomized trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet, 2000, 356: 2139-2143.
5Todd W, Rice, Arthur P,et al. Severe Sepsis. Medscape, 2003,20: 184-193.
6Martin C, Viviand X, Leone M, et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med ,2000,28: 2758-2765.
7Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology ,2002,96: 576-582.
8Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med,2001,344: 699-709.
9Matthay MA. Severe sepsis- a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med ,2001,344: 759-762.
10Warren BL, Eid A, Singer P, et al. High-does antithrombin III in severe sepsis: a randomized controlled trial. JAMA ,2001,286: 1869-1878.
